Somnomed Ltd
OTC:SOMNF
Somnomed Ltd
SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.
SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.
Record Revenue: SomnoMed reported a record half-year revenue of $60.7 million, up 13% year-on-year, driven by strong demand in Europe and North America.
EBITDA Growth: EBITDA rose 35% to $7.8 million, with margin improving from 11% to 13%, supported by operating leverage and timing of investments.
Guidance Reaffirmed: Management reaffirmed full-year FY '26 guidance for revenue of $119–126 million and EBITDA of $10–12 million.
Capacity & Efficiency: Manufacturing capacity increased by over 20%, leading to significantly improved turnaround times and additional headroom for future demand.
Innovation Update: The Rest Assure device received FDA clearance for compliance monitoring; management is exploring ways to accelerate commercialization using this clearance.
Cash Position: The company ended the half with $18 million in cash and minimal borrowings, supporting ongoing investments in manufacturing and R&D.
